Drug Delivery Platform Articles & Analysis
42 news found
CD Formulation's transdermal patch drug delivery system services are designed to optimize formulations, ensuring the efficient and precise delivery of drugs across the skin barrier. ...
In recent years, the field of drug delivery has witnessed great advancements in the development of microspheres and microneedles, revolutionizing the way drugs are administered. ...
CD Formulation, a reputable contract research organization (CRO) based in New York, has become a trusted partner for many pharmaceutical companies around the world seeking innovative drug formulation methods and solutions. Recently, CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the ...
BOC Sciences, a leading supplier of research chemicals and custom services, has unveiled its innovative XDC bioconjugation platform, providing a significant tool for drug delivery. The newly developed XDC bioconjugation platform offered by BOC Sciences introduces a range of advanced technologies and optimized protocols, ...
About CTx-1301 Cingulate’s lead candidate, CTx-1301, utilizes the Company’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. ...
Prior to Beta Bionics, Rao spent over a decade working for Eli Lilly in a number of commercial and technical roles including Vice President of External Innovation in the Lilly Device, Delivery, and Digital Health groups. Rao has a PhD in Chemical Engineering from Stanford University and an MBA from the University of Virginia Darden School of Business. ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. ...
About CTx-1301 Cingulate’s lead candidate, CTx-1301, utilizes the Company’s proprietary PTR™ drug delivery platform to create a breakthrough, multi-core formulation of the API dexmethylphenidate, a compound approved by the U.S. ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has executed a Master Services Agreement (MSA) with Societal CDMO, Inc. ...
Davies-Cutting will contribute his extensive respiratory product development and industry expertise to the development and commercialization of Nob Hill Therapeutics’ first-of-its-kind DryNeb dry powder nebulizer inhalation drug delivery platform. “We are thrilled to have Craig on the Nob Hill team,” said Noel Greenberger, ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced findings from its formulation study for CTx-2103, the Company’s asset for the management of anxiety-related ...
(NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced completion of the formulation study for its third asset, CTx-2103, for the management of ...
The rapidly dissolving yarn is a key element in the innovative EsoCap system which enables local placement of drug-loaded films and targeted, long-lasting drug delivery in the esophagus (Rosenbaum et al., Pharmaceutics 2022, 14, 1229). ...
The experts discussed the role of EsoCap’s technology for the topical treatment of Barrett esophagus and explored the application of EsoCap’s drug delivery platform in combination with monoclonal antibodies, siRNA-based technology, oncology drug substances as well as other agents. ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a dynamic lipid library for optimized ...
Flowonix Medical and Miratech Medical today announced the acquisition of the U.S. distribution rights to Flowonix’s state-of-the-art targeted drug delivery system for the treatment of chronic pain and spasticity by Miratech Medical in a transaction that closed on May 11th. ...
Gerresheimer AG is expanding its portfolio of highly-innovative platform technologies for drug delivery. Gerresheimer, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, today announced an investment into US-based Portal Instruments, a developer of ...
With the additional secured funding, as well as the poster’s reception by a leading eye care practitioner society, MediPrint’s platform drug delivery technology has now been further validated by both the investment and the eye care professional communities. ...
(NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. ...